Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of these INSTIs in the last two years. A retrospective observational study in patients who started DTG or EVG/COBI from January 2015 to January 2017 at a reference hospital in north-western Spain was done. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed with SPSS software. A total of 542 DTG (n = 275)- or EVG/COBI (n = 267)-based therapies were initiated during the study period. Overall, more than 90% of naïve and pre-treated patients had virological suppression in both groups after 48 weeks of initiation of treatment per-protocol snapshot analysis. During follow-up, 10.2% of patients were treated with DTG and 4.5% of those treated with EVG discontinued due to adverse events (AE). In the case of DTG mainly related to neuropsychiatric disturbances (70.4%) and for EVG/COBI with gastrointestinal discomfort (50%). Female sex [HR 2.255 (95%CI 1.121-4.535), p = 0.023] and DTG treatment [HR 2.453 (95%CI 1.221-4.931), p = 0.012] were associated with AE discontinuations. Specifically for neuropsychiatric events, DTG treatment [HR 5.906 (95%CI 1.954-17.846), p = 0.002] and receiving abacavir/lamivudine/DTG [HR 4.380 (95%CI 1.348-14.233), p = 0.014] were identified as predictive risk factors for treatment discontinuations in two different multivariate analyses. A high percentage of AE discontinuations not previously described in clinical trials has been observed, especially with DTG. Female gender and DTG treatment were identified as risk factors for AE discontinuation. DTG-based therapies, especially in combination with abacavir/lamivudine, were associated with an increased risk of treatment discontinuation due to neuropsychiatric AE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcpt.12828 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurodevelopmental outcomes in children exposed in utero to dolutegravir- or efavirenz-based ART.
AIDS
January 2025
Botswana Harvard Health Partnership, Gaborone, Botswana.
Objective: To examine the impact of in utero exposure to dolutegravir (DTG)- or efavirenz (EFV)-based antiretroviral treatment (ART) on child neurodevelopmental (ND) outcomes.
Design: Prospective cohort design, enrolling 3 cohorts of 2-year-olds: children HIV-negative born to mothers with HIV (CHEU) receiving either DTG-based or EFV-based 3-drug ART during pregnancy, and children born to mothers without HIV (CHUU).
Methods: Primary child ND outcomes were assessed using the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) and compared between cohorts using generalized estimating equation models adjusted for confounders.
The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis.
AIDS
November 2024
Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Objective: Fixed dose combination (FDC) dolutegravir (DTG) plus rilpivirine (RPV) is an approved antiretroviral treatment regimen for people with HIV. The steady-state pharmacokinetics (PK) of FDC DTG+RPV in hemodialysis (HD) has not been previously studied.
Design: We performed a single-center, prospective evaluation of the steady-state PK of FDC DTG +RPV in 4 adults without HIV either requiring HD and in 4 matched participants with normal renal function.
Trends and factors associated with HIV viral load non-suppression among treatment-experienced female sex workers in Kenya: a retrospective cohort study.
AIDS
January 2025
Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Busia, Kenya.
Background: Transactional sexual relations in the absence of condom use is a well-established behaviour that strongly contributes to HIV transmission if the infected person is not virally suppressed. In this study, we determined the trends and factors associated with VLNS among treatment-experienced FSWs in Kenya.
Methods: This retrospective cohort study used data collected from 7-sex workers outreach clinics between 2015 and 2022.
Propyl paraben removal using CuO/ZnO-NPs photocatalyst elaborated via green method.
Environ Sci Pollut Res Int
January 2025
CPRAC Research Center, Centre de Recherche Scientifique et Technique en Analyses Physico-Chimiques, Bou-Ismail CP, Tipaza, 42004, Algeria.
The aim of the present work is to investigate the photocatalytic degradation of propyl paraben (propyl para-hydroxybenzoate, PrP) using CuO-ZnO-NPs photocatalyst followed by the identification of the oxidation by-products. The CuO-ZnO-NPs material, synthesized using a green chemistry approach, was used as a photocatalyst for the removal of PrP. The nanoparticles were characterized by XRD, XRF, diffuse reflectance spectroscopy, ATG/DTG, FTIR, SEM-EDX, BET and FRX techniques.
View Article and Find Full Text PDFAdherence and forgiveness of two modern ART regimens: lamivudine/dolutegravir and emtricitabine/tenofovir alafenamide/rilpivirine.
J Acquir Immune Defic Syndr
January 2025
Infectious Disease Clinic, IRCCS Policlinico San Martino Hospital, Genoa.
Introduction: Few data are available about the forgiveness of two-drug (2DR) or low-barrier three-drug antiretroviral regimens. The aim of this study is to evaluate the real-life forgiveness of lamivudine/dolutegravir (3TC/DTG) and emtricitabine/tenofovir alafenamide/rilpivirine (FTC/TAF/RPV).
Methods: A two center retrospective observational study enrolled all people with HIV (PWH) treated with 3TC/DTG or FTC/TAF/RPV.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!